Market capitalization | $10.39m |
Enterprise Value | $67.49m |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 0.26 |
P/S ratio (TTM) P/S ratio | 0.04 |
Short interest | 4.19% |
As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.
2 Analysts have issued a Eagle Pharmaceuticals, Inc. forecast:
2 Analysts have issued a Eagle Pharmaceuticals, Inc. forecast:
Dec '22 |
+/-
%
|
||
Revenue | 317 317 |
85%
85%
|
|
Gross Profit | 221 221 |
71%
71%
|
|
EBITDA | 107 107 |
1,309%
1,309%
|
EBIT (Operating Income) EBIT | 94 94 |
3,278%
3,278%
|
Net Profit | 36 36 |
513%
513%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Eagle Pharmaceuticals, Inc. engages in the provision of injectable products. Its products include argatroban, ryanodex, docetaxel injection, non-alcohol formulation and bendeka. The company was founded by Scott L. Tarriff on January 2, 2007 and is headquartered in Woodcliff Lake, NJ.
Head office | United States |
CEO | Michael Graves |
Founded | 2007 |
Website | www.eagleus.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.